An Adaptive, Seamless Phase 1, Followed by a Phase 2, Randomized, Multicenter Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Whole Virion Inactivated SARS-CoV- 2 Virus Vaccine, BBV152D Administered Intradermally in Healthy Volunteers. - COVID ID STUDY
Latest Information Update: 27 Nov 2020
At a glance
- Drugs BBV 152 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms COVID ID STUDY
- Sponsors Bharat Biotech
- 27 Nov 2020 New trial record